@the_news_21
Indigenous vaccine company Bharat Biotech is all set to conduct phase three trial of coronavirus vaccine. However, as per report the company has set a target for a launch of the vaccine when all the reports come clear. The Hyderabad-based firm plans to have ‘Covaxin’ ready by June 21, Sai Prasad, executive director, Bharat Biotech International Ltd, said.
“If we get all the approvals in place, I think during Q2 of 2021, we should get the efficacy readout from our phase-3 clinical trial — April, May, June, for example. That is for the full efficacy results,” Prasad was quoted as saying by The Indian Express.
Covaxin is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research’s (ICMR) National Institute of Virology.
In July, the Drug Controller General of India (DCGI) had given permission to Bharat Biotech to conduct phase 1 and 2 clinical trials of its COVID-19 vaccine.
